EUCTR2006-004784-58-GB进行中（未招募）1 期
An Open Label, Prospective, Multi-Center Trial on the Effect of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) on Inflammatory and Fibrous Lesions in Patients with Intestinal Crohn's Diesease. ACTIF Trial. - Effect of Infliximab on MRI lesions in Crohn's - ACTIF study
niversity of Leuven Hospitals0 个研究点目标入组 25 人开始时间: 2009年4月30日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for the trial, patients must meet all of the following inclusion criteria:
- •1)Men and women = 18 and = 65 years of age,
- •2)Are capable of understanding and signing an informed consent
- •3)Are considered eligible according to the following tuberculosis (TB) screening criteria:
- •a)Have no history of latent or active TB prior to screening
- •b)Have no signs or symptoms suggestive of active TB upon medical history or physical examination
- •c)Have had no recent close contact with a person with active TB
- •d)Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of infliximab and read by a qualified radiologist, with no evidence of current active TB or old inactive TB.
- •4)The presence of active disease:
- •a)CDAI > 220
- •b)CRP > 5 mg/L (see amendment to protocol)
- •5)Strong Gadolinium (Gd) uptake on baseline contrast enhanced MRI enteroclysis (see MRI manual)
- •6)Ileal wall thickening of > 4 mm on baseline contrast enhanced MRI enteroclysis
- •7)Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last medication
排除标准
- •Patients who meet any of the following criteria may not be enrolled in the study:
- •1)Have a medical contraindication for MRI enteroclysis (eg metal implants, including metal prosthetic heart valve(s), implantable devices, including a cardiac pacemaker and severe claustrophobia)
- •2)use more than 15 mg of oral steroids (prednisone or equivalent) within the 2 weeks prior to baseline MRI. IV use of steroids is not allowed within that same period
- •3)Have a severe prestenotic dilation of the ileum on screening MRI (severe dilation is defined as > 2 times the luminal diameter of the unaffected ileum)
- •4)Have had bowel resection of > 100 cm
- •5)Have presence of an abdominal abscess
- •6)Have MRI enteroclysis confirmed internal fistula
- •7)Be considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section on: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation Rules (refer to sections 5.9 and 18).
- •8)Have Screening laboratory test results as follows:
- •a)White blood cells (WBCs) < 3.0 x 109 cells/L
- •b)Platelets < 100 X 109 cells/L
- •c)Serum creatinine > 132 µmol/L (> 1,5 mg/dL)
- •d)Serum transaminase levels exceeding 2 times the upper limit of normal for the site laboratory
- •9)Have had any previous treatment with monoclonal antibodies or antibody fragments
- •10)Have a history of receiving human/murine recombinant products or a known allergy to murine products
- •11)Have documentation of seropositivity for human immunodeficiency virus (HIV)
- •12)Have a positive test for hepatitis B surface antigen or hepatitis C
- •13)History of alcohol or substance abuse in the 6 months prior to the study
- •14)Have a known history of serious infections (eg, hepatitis, pneumonia, or pyelonephritis) in the previous 3 months
- •15)Have a known history of a demyelinating disease, such as multiple sclerosis
- •16)Have or have had an opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria othe
研究者
相似试验
已完成
不适用
Study for reduction of Eye PressureCTRI/2018/03/012458iSTAR Medical SA10
已完成
不适用
Study for reduction of Eye PressureCTRI/2018/02/012240iSTAR Medical SA15
进行中（未招募）
1 期
An open label, prospective, multicenter trial, on the effect of anti-TNF alpha Chimeric monoclonal antibody (Infliximab, Remicade) on the inflammatory and fibrous lesions in patients with intestinal Crohn's Disease.Crohn's diseaseEUCTR2006-004784-58-FRCHRU de Lille25
进行中（未招募）
不适用
An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia BHaemophilia BMedDRA version: 15.1Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2010-023070-40-ATovo Nordisk A/S16
进行中（未招募）
不适用
An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - paradigm™3EUCTR2010-023070-40-NLovo Nordisk A/S16